Non-Adherence to Antidepressant Treatment and Related Factors in a Region of Spain: A Population-Based Registry Study
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Antidepressants are a commonly prescribed psychotropic medication, and their use has increased in recent years. Medication non-adherence in patients with mental disorders is associated with worse health outcomes. A population-based registry study to assess antidepressant non-adherence during 2021 has been carried out. An indirect method based on the medication possession ratio (MPR) has been utilized. Patients with a MPR under 80% were classified as non-adherent. A multivariate logistic regression to identify non-adherence predictors has been used, considering sociodemographic (age, sex, institutionalization and urbanicity) and health related variables (diagnostics, antidepressant class, multiple prescribers, and polypharmacy). In 2021, 10.6% of the Castile and Leon population used antidepressants. These patients were institutionalized (7.29%), living in urban areas (63.44%), polymedicated with multiple prescribers (57.07%), and using serotonin selective reuptake inhibitors (SSRIs) (54.77%), other antidepressants (46.82%) or tricyclic antidepressants (TCAs) (13.76%). Antidepressants were prescribed mainly for depression (36.73%) and anxiety (29.24%). Non-adherence to antidepressants was more frequent in men (20.56%) than in woman (19.59%) and decreased with increasing age (32% up to 17 years old vs. 13.76% over 80 years old). TCAs were associated with the highest prevalence of non-adherence (23.99%), followed by SSRIs (20.19%) and other antidepressants (18.5%). Predictors of non-adherence in patients on antidepressants were: living in urban areas, using TCAs, and pain occurrence. Non-adherence to antidepressants decreases with aging. Being female, institutionalization, being polymedicated and having depression/anxiety alongside another psychiatric diagnosis are protective factors against non-adherence. The MPR is a robust indicator for the clinician to identify non-adherent patients for monitoring, and adopt any necessary corrective actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using this definition, about 30- 50% of persons prescribed with antidepressants are non- adherent in acute phase treatment 169 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A replicated observation is the high rate of non- adherence to antidepressants in persons with MDD.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [169]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02143-7 · Cited by 5,444
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,079
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Mirowsky, J., & Ross, C. E. (1992) · Journal of Health and Social Behavior · doi:10.2307/2137349 · Cited by 837
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Zewdu, W. S., Dagnew, S. B., Tarekegn, G. Y., Yazie, T. S., Ayicheh, M. A., Dagnew, F. N., & Moges, T. A. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06838-9 · Cited by 23
Ishtiak‐Ahmed, K., Köhler‐Forsberg, O., Mortensen, E. L., Nierenberg, A. A., & Gasse, C. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01018-4 · Cited by 17
Muhammad, N., Ullah, S. R., Nagi, T. K., & Yousaf, R. A. (2023) · Cureus · doi:10.7759/cureus.37828 · Cited by 16
del Pino‐Sedeño, T., González‐Pacheco, H., de León, B. G., Serrano-Pérez, P., Acosta, F. J., Valcárcel‐Nazco, C., Hurtado, I., Álvarez, C. R., Trujillo‐Martín, M. M., & on behalf of MAPDep Team (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1320159 · Cited by 13
Infante‐Ventura, D., Rodriguez-Díaz, B., Bello, M. Á. G., Valcárcel‐Nazco, C., Estupiñán‐Romero, F., Acosta, F. J., de León, B. G., Hurtado, I., & del Pino‐Sedeño, T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119443 · Cited by 12
Gutiérrez‐Abejón, E., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Planelles, I. D., & Alvarez, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1425442 · Cited by 11
Self-citationTreatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
Mora, F., Ramos‐Quiroga, J. A., Baca‐García, E., Crespo, J. M., Gutiérrez-Rojas, L., Madrazo, A., Pérez-Costillas, L., Sáiz, P. A., Tordera, V., & Vieta, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623659 · Cited by 11
Medication economic burden of antidepressant non-adherence in Spain
Gutiérrez‐Abejón, E., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., & Alvarez, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1266034 · Cited by 10
Self-citationDeterminants of adherence to treatment in patients with ophthalmic conditions
Muñoz‐Villegas, P., Martínez-Bautista, H., & Olvera‐Montaño, O. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279740 · Cited by 10
Martín-Fernández, M., González-González, M. A., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Alvarez, E., & Gutiérrez‐Abejón, E. (2025) · Pharmaceuticals · doi:10.3390/ph18050634 · Cited by 9
Self-citationGonzález-González, M. A., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Planelles, I. D., Alvarez, E., & Gutiérrez‐Abejón, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1642470 · Cited by 8
Self-citationChen, S., Database, T. E., Cardinal, R. N., Auckland, K., Gräf, S., O'Brien, J. T., & Underwood, B. R. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221093 · Cited by 7
Munira, L., Liamputtong, P., Herman, B. Z., & Viwattanakulvanid, P. (2025) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-025-02819-1 · Cited by 6
Costa, T. D. S., Hall, B., Hill, S., Teama, R., Romaine, E., Ahmed, S., McKinnon, I., Watson, S., Bagnall, A. J., Kenny, R. P. W., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261433212 · Cited by 4
Jawed, A., & Zaim, N. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166578 · Cited by 4
Lee, S., Li, C., Chang, Y., Wang, Y., Chen, C.-Y., & Tsai, Y. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.05.006 · Cited by 4
Pigato, G., Meda, N., Paladin, M., Toffanin, T., Artusi, C., & Sambataro, F. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000610 · Cited by 3
Bağcaz, A., & Özel, B. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1752173 · Cited by 2
Jamal, I., Ali, A. M., Gul, E., Muslim, M., Muneeb, P. M., & Sumaira (2024) · Journal of Saidu Medical College · doi:10.52206/jsmc.2024.14.1.778 · Cited by 1
Kawaii-Bogue, B., MacNear, K. A., Dixon-Gardner, A., Bobo, K., Okafor, C., Cook, E., & Soares, K. (2025) · Mental Health Religion & Culture · doi:10.1080/13674676.2025.2520501 · Cited by 1
Godbout-Parent, M., Julien, N., Nguefack, H. L. N., Pagé, M. G., Guénette, L., Blais, L., Ménard, N., Beaudoın, S., & Lacasse, A. (2026) · Frontiers in Pain Research · doi:10.3389/fpain.2026.1810867 · Cited by 1
Sun, Q., Yeung, P. W. C., Yan, J. J., & Lai, F. T. T. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121836 · Cited by 1
Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update
Marques, M. G., & Singh, B. (2026) · Psychopharmacology Bulletin · doi:10.64719/pb.18522 · Cited by 1
Herranz, R. M. G. D. M., Rujas, M., Arroyo, P., Carlson, J. I., Cortés, J. B., Villimar-Rodríguez, A. I., Morros, R., Giner‐Soriano, M., Castillo-Sanz, A., Lupiáñez‐Villanueva, F., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-61269-0 · Cited by 1
Medication Adherence Views of Mental Health Nurses to Inspire Transformative Care
Alyahya, N. M. (2026) · Creative Nursing · doi:10.1177/10784535261490954 · Cited by 1
A Systematic Review: Effectiveness Of Different Routes Of Administration For Antidepressants
Jetithor, S. V. (2025) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i6s.8504
Zewdu, W. S., Zerihun, T. E., Mussie, D. A., Kassaw, A. T., Yazie, T. S., & Moges, T. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251387413
Boruzs, K., Dombrádi, V., & Bíró, K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s562457
Pedrosa-Naudín, M. A. (2026) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/83327
Self-citationFebrianti, Y., Puspitasari, I., Widayanti, A. W., & Setiyawati, D. (2026) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v15i1.25537
Delgado, S. C. (2025) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Godbout-Parent, M. (2026) · Depositum (Université du Québec en Abitibi-Témiscamingue)
Lee, X., Usman, J., Hamzah, N., Yeoh, P. S. Q., Wu, X.-D., Chuah, J. H., & Lai, K. W. (2026) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2026.103405
Aziz, M. A., Maruf, A. A., Bolton, J. M., Kowalec, K., Eltonsy, S., Friesen, K. J., & Leong, C. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08482-3
Clinical outcomes of psychotic depression in Sweden: a nationwide register study
Al‐Wandi, A., & Nordenskjöld, A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122400
González-González, M. A., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Planelles, I. D., Alvarez, E., & Gutiérrez‐Abejón, E. (2026) · Pharmaceuticals · doi:10.3390/ph19101607
Self-citationSalehian, M. H. (2026) · Physical Activity in Children · doi:10.66224/pach.2026.588084.1095
Ohene, H. (2026) · ScholarWorks (Walden University)
Metadata
- Authors
- Pedrosa-Naudín, M. A., Gutiérrez-Abejón, E., Herrera-Gómez, F., Fernández-Lázaro, D., & Álvarez, F. J.
- Affiliations
- Gerencia Regional de Salud de Castilla y León (Sacyl) (ES)
- Pharmacy Directorate, Castilla y León Health Council, 47007 Valladolid, Spain
- Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
- Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, Campus of Soria, University of Valladolid, 42003 Soria, Spain
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-02
- Volume
- 14
- Issue
- 12
- Pages
- 2696
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9782667
- OpenAlex
- W4311098684
- Cited by
- 31
- References
- 67
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 4 · 2023: 7
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Hispana (publishedVersion, cc-by)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) (submittedVersion, cc-by)
- Funders
- Instituto de Salud Carlos III, Redes Temáticas de Investigación Cooperativa, Red de Trastornos Adictivos (RD16/0017/0006)
- the European Regional Development Fund (ERDF) (RD16/0017/0006)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- medication possession ratio, antidepressants, tricyclic antidepressants, selective serotonin reuptake inhibitors, polypharmacy, multiple prescribers, depression, anxiety, institutionalization, urbanicity, age differences, sex differences, pain, Castilla y León
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
